Mivebresib (ABBV-075) is a small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor being studied in a Phase 1 clinical trial in patients with advanced hematologic malignancies and solid tumors.

Type of Molecule

Small Molecule

Target

BET

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Acute Myeloid Leukemia (AML) New Indication Phase 1
Multiple Myeloma (MM) New Indication Phase 1
Solid Tumors New Indication Phase 1